

Help

Bloomberg

Company In Depth Fundamentals - Profile

Ticker: **PFE US EQUITY**

Pfizer Inc (New York: PFE, Currency: USD)

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website: www.pfizer.com
 Number of Employees: 79,000
 Ticker: PFE US

235 East 42nd Street New York, NY 10017 United States
 Phone : 1-212-733-2323
 Fax : 1-212-573-7851

51.64 -0.02 (-0.04%)

Pfizer Inc. opera como una empresa farmacéutica. Ofrece medicamentos, vacunas, dispositivos médicos y productos sanitarios de consumo para los sectores de oncología, inflamación, cardiovascular y otros de terapia. Atiende a clientes en todo el mundo.

Stock Quote & Chart (Currency: USD)

Last (delayed quote)	51.64	Market Cap (MM)	289,871.6
Open	51.41	Shares Out. (MM)	5,613.3
Previous Close	51.66	Float %	99.9%
Change	0.34	Shares sold short (MM)	62,827,686.0
Change %	0.66	Dividend Yield %	3.1
Day High/Day Low	51.7 / 51.0	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	60.6 / 41.4	P / Diluted EPS Before XO	
Volume (MM)	14.82	Beta	0.71
Avg. Vol - 3 mo (MM)	21.38		



Financial Information (Currency: USD, in mm)

Revenue - LTM	99,879.0	Cash & ST Invest.	31,069
EBIT - LTM	33,554.0	Total Assets	181,476.0
EBITDA - LTM	38,376.0	Total Debt	41,395.0
Net Income - LTM	29,771.0	Total Liabilities	104,014.0
Total Enterprise Value	290,677	Total Equity	77,462.0
TEV/ Total Revenue	2.5 x	Cash from Operations - LTM	30,559.0
TEV/ EBITDA	6.4 x	Cash From Investing - LTM	-17,919.0
		Cash from Financing -LTM	-13,336.0

Company Notes

2015 Q3	
GAAP Net Income Includes: (in millions, pre-tax)	2014 Q1
A loss of \$470,000 from Asset Write Down	GAAP Net Income Includes: (in millions, pre-tax)
A loss of \$479,000 from Restructuring	A loss of \$140 from Restructuring
A loss of \$163,000 from Impairment of Intangibles	A loss of \$694 from Legal Expense
A loss of \$124,000 from Merger & Acquisition.	A loss of \$139 from Impairments and M & A Expense
A gain of \$35,000 from Disposal of assets.	A gain of \$210 from Asset Disposal, Derivatives, and other
A loss of 92,000 from various one time items.	
2015 Q2	
GAAP Net Income Includes: (in millions, pre-tax)	2013 A1
A loss of \$304,000 from Other One Time Items	GAAP Net Income Includes: (in millions, pre-tax)
A loss of \$25,000 from Asset Write Down	A loss of \$1431 from Restructuring, A gain of \$1321 from Legal Expense, A loss of \$144 from M & A Expense, A gain of \$38 from Derivatives, A loss of \$1224 from Impairments, A gain of \$125 from Asset Disposal, A gain of \$195 from Sale of Investment
A loss of \$68,000 from Merger/Acquisition Expense	A gain of \$10,623,000 from Discontinued Operations
A gain of \$ 5,000 from Investments, a gain from \$ 15,000 from disposal of asset, A loss of \$25,000 from impairment of asset	
2015 Q1	
GAAP Net Income includes, (in millions, after-tax):	2013 Q4
a loss of \$17,000 from Acquisition/Merger	GAAP Net Income Includes: (in millions, pre-tax)
a loss of \$167,000 from Various One-Time Items	A loss of \$708 from Restructuring, A loss of \$120 from Legal Expense, A loss of \$34 from M & A Expense, A gain of \$5 from Derivatives, A loss of \$176 from Impairments, A gain of \$125 from Assets Disposal, A gain of \$95 from Sale of Investment
a gain of \$5,000 from Discontinued Operations	a loss of \$58,000 from Discontinued Operations
2014 A1	
GAAP Net Income includes, (in millions):	2013 Q3
a pre-tax gain of \$288,000 from Disposal of Assets	GAAP Net Income includes, (in millions, after-tax):
a pre-tax loss of \$1,630,000 from Impairment/Legal	a loss of \$54,000 from Acquisition/Merger
a pre-tax loss of \$250,000 from Restructuring/Acquisition	a loss of \$1,223,000 from Various One-Time Items
an after-tax gain of \$48,000 from Discontinued Operations	a gain of \$11,000 from Discontinued Operations


Key Board Members

Name	Title	Organization
Ronald E Blaylock "Ron"	Managing Partner/Co-Founder	Gennx360 Capital Partners
	Founder	Blaylock & Co Inc
	Board Member	Pfizer Inc
	Board Member	Carmax Inc
	Board Member	Wf Berkley Corp
	Board Member	Mebane Charitable Foundation I
Susan Desmond-Hellmann "Sue"	Board Member	Pfizer Inc
	Board Member	National Resilience Inc
	Board Member	Pfizer Venture Investments
	Board Member	Brookings Institution/The
Suzanne Nora Johnson	Co-Chairman	Intuit Inc
	Chairman	Pfizer Inc
	Board Member	University Of Southern Califor
	Trustee	John & Mary R Markle Foundatio
	Chairman	Carnegie Institution Of Washin
	Trustee	University Of Southern Califor
	Board Member	Women'S World Banking Inc
Shantanu Narayen	Board Member	Technoserve Inc
	Board Member	Council For Excellence In Govt
	Board Member	Children Now Inc
	Board Member	American Red Cross
	Board Member	Visa Intl Inc
	Chairman/President/Ceo	Adobe Ventures Lp
	Co-Founder	Pictra Inc
	Vice Chairman	Us-India Strategic Partnership
	Chairman/Ceo	Adobe Inc
	Lead Director	Pfizer Inc
Susan Hockfield	Chairman	Adobe Foundation
	Overseer	Boston Symphony Orchestra Inc

Ticker:	PFE US EQUITY										
Period Type:	Annuals										
Annuals	Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos										
FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY


Key Financials	Actuals											LTM		Estimates	
	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	02/10/2022	02/10/2022	31/12/2022	31/12/2023	31/12/2024				
For the Fiscal Period Ending	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD			
Total Revenue	48,851.0	52,824.0	52,546.0	53,647.0	40,905.0	41,908.0	81,288.0	22,638.0	81,288.0	24,377.2	24,377.2				
Growth Over Prior Year	(1.5%)	8.1%	(0.5%)	2.1%	(23.8%)	2.5%	94.0%	44.6%	2.3%	2.3%	2.3%				
Gross Profit	39,203.0	40,495.0	41,318.0	42,399.0	32,851.0	33,216.0	50,467.0	65,448.0	--	--	--				
Margin %	80.3%	76.7%	78.6%	79.0%	80.3%	79.3%	62.1%	289.1%	--	--	--				
EBITDA	16,981.0	17,763.0	19,991.0	20,385.0	20,948.0	13,336.0	25,131.0	38,376.0	7,187.8	7,187.8	7,187.8				
Margin %	34.8%	33.6%	38.0%	38.0%	51.2%	31.8%	30.9%	169.5%	8.8%	29.5%	29.5%				
EBIT	11,824.0	12,006.0	13,722.0	14,001.0	14,817.0	8,166.0	19,433.0	33,554.0	6,670.2	6,670.2	6,670.2				
Margin %	24.2%	22.7%	26.1%	26.1%	36.2%	19.5%	23.9%	148.2%	8.2%	27.4%	27.4%				
Earnings from Cont. Ops.	6,975.0	7,228.0	21,353.0	11,179.0	10,738.0	7,020.0	22,459.0	29,979.0	--	--	--				
Margin %	14.3%	13.7%	40.6%	20.8%	26.3%	16.8%	27.6%	132.4%	--	--	--				
Net Income	6,960.0	7,215.0	21,308.0	11,153.0	16,026.0	9,616.0	21,979.0	29,771.0	6,109.8	6,109.8	6,109.8				
Margin %	14.2%	13.7%	40.6%	20.8%	39.2%	22.9%	27.0%	131.5%	7.5%	25.1%	25.1%				
Diluted EPS Excl. Extra Items	1.1	1.2	3.5	1.9	1.9	1.2	3.9	5.2	1.1	1.1	1.1				
Growth Over Prior Year	(21.3%)	5.4%	200.9%	(47.2%)	1.6%	(34.4%)	216.9%	52.9%	(1.4%)	(1.4%)	(1.4%)				

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	51.64
Shares Out.	5,613.32
Market Capitalization (USD)	289,871.56
- Cash & Short Term Investments	36,123.00
+ Total Debt	36,669.00
+ Pref. Equity	0.00
+ Total Minority Interest	259.00
= Total Enterprise Value (USD)	290,676.56
Book Value of Common Equity	92,632.00
+ Pref. Equity	0.00
+ Total Minority Interest	259.00
+ Total Debt	36,669.00
= Total Capital	129,560.00



Valuation Multiples based on Current Capitalization	Actual		Estimates		
	02/10/2022	02/10/2022	02/10/2022	02/10/2022	02/10/2022
TEV/Total Revenue	4.2x	2.5x	11.0x	11.0x	11.0x
TEV/EBITDA	13.6x	6.4x	8.8x	8.8x	8.8x
TEV/EBIT	17.6x	7.3x	9.4x	9.4x	9.4x
P/Diluted EPS Before Extra	15.0x	8.4x			
P/BV	4.3x	2.7x	2.9x	2.9x	2.9x
Price/Tang BV	116.6x	16.3x			

Valuation Multiples for Chart	For the Fiscal Period Ending			
	TTM	FY1	NTM	FY2
PE Ratio	8.5x	11.7x	11.7x	11.7x
TEV / EBITDA	6.4x	8.8x	8.8x	8.8x
Price / CF	9.5x	0.0x	0.0x	0.0x
Price / Book	3.1x	2.9x	2.9x	2.9x
Dividend Yield	3.1x	4.9x	4.9x	4.9x



Ticker:	PFE US EQUITY
Period Type	Annuals

PFE US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:											
Currency	31/12/2011 USD	31/12/2012 USD	31/12/2013 USD	31/12/2014 USD	31/12/2015 USD	31/12/2016 USD	31/12/2017 USD	31/12/2018 USD	31/12/2019 USD	31/12/2020 USD	31/12/2021 USD
Revenue	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00
Other Revenue	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00
Cost Of Goods Sold	14,076.00	9,821.00	9,586.00	9,577.00	9,648.00	12,329.00	11,228.00	11,248.00	8,054.00	8,692.00	30,821.00
Gross Profit	51,183.00	44,836.00	41,998.00	40,028.00	39,203.00	40,495.00	41,318.00	42,399.00	32,851.00	33,216.00	50,467.00
Selling General & Admin Exp.	21,762.00	16,981.00	15,537.00	14,347.00	15,961.00	16,561.00	15,155.00	15,499.00	5,220.00	12,209.00	13,505.00
R & D Exp.	9,074.00	7,482.00	6,678.00	8,393.00	7,690.00	7,872.00	7,683.00	8,006.00	8,385.00	9,405.00	13,829.00
Depreciation & Amort.	5,544.00	5,109.00	4,599.00	4,039.00	3,728.00	4,056.00	4,758.00	4,893.00	4,429.00	3,436.00	3,700.00
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	36,380.00	29,572.00	26,814.00	26,779.00	27,379.00	28,489.00	27,596.00	28,398.00	18,034.00	25,050.00	31,034.00
Operating Income	14,803.00	15,264.00	15,184.00	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,817.00	8,166.00	19,433.00
Interest Expense	1,681.00	1,522.00	1,414.00	1,360.00	1,199.00	1,186.00	1,270.00	1,316.00	1,573.00	1,449.00	1,291.00
Interest Income	456.00	382.00	403.00	425.00	471.00	470.00	391.00	333.00	225.00	73.00	36.00
Net Interest Exp.	1,225.00	1,140.00	1,011.00	935.00	728.00	716.00	879.00	983.00	1,348.00	1,376.00	1,255.00
Currency Exchange Gains (Loss)	-	-	-	-	806.00	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	1,274.00	2,882.00	(1,543.00)	74.00	1,325.00	2,939.00	538.00	1,133.00	2,148.00	(707.00)	(6,133.00)
EBT Excl. Unusual Items	12,304.00	11,242.00	15,716.00	12,240.00	8,965.00	8,351.00	12,305.00	11,885.00	11,321.00	7,497.00	24,311.00
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	12,304.00	11,242.00	15,716.00	12,240.00	8,965.00	8,351.00	12,305.00	11,885.00	11,321.00	7,497.00	24,311.00
Income Tax Expense	3,909.00	2,221.00	4,306.00	3,120.00	1,990.00	1,123.00	(9,048.00)	706.00	583.00	477.00	1,852.00
Earnings from Cont. Ops.	8,395.00	9,021.00	11,410.00	9,120.00	6,975.00	7,228.00	21,353.00	11,179.00	10,738.00	7,020.00	22,459.00
Extraord. Item & Account. Change	(1,654.00)	(5,577.00)	(10,662.00)	(48.00)	(11.00)	(18.00)	(2.00)	(10.00)	(5,318.00)	(2,631.00)	434.00
Minority Int. in Earnings	40.00	28.00	69.00	33.00	26.00	31.00	47.00	36.00	30.00	35.00	46.00
Net Income	10,009.00	14,570.00	22,003.00	9,135.00	6,960.00	7,215.00	21,308.00	11,153.00	16,026.00	9,616.00	21,979.00
Pref. Dividends	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	10,006.00	14,568.00	22,001.00	9,133.00	6,958.00	7,213.00	21,307.00	11,152.00	16,026.00	9,616.00	21,979.00
Abnormal Losses (Gains)	6,326.00	5,985.00	1,106.00	3,618.00	5,369.00	8,789.00	2,554.00	3,429.00	(2,791.00)	3,849.00	2,533.00
Tax Effect on Abnormal Items	(1,842.00)	(2,791.00)	(344.00)	(1,266.30)	(1,879.15)	(3,076.15)	(11,396.54)	(1,049.67)	(813.89)	(813.67)	(414.20)
NI to Common Excl. Extra Items	14,490.00	17,762.00	22,763.00	11,484.70	10,447.85	12,925.85	12,464.46	13,531.33	12,421.11	12,651.33	24,097.80
Per Share Items											
Basic EPS	1.28	1.96	3.23	1.44	1.13	1.18	3.57	1.90	2.88	1.73	3.92
Basic EPS Excl. Extra Items	1.07	1.21	1.67	1.43	1.13	1.18	3.57	1.90	1.92	1.26	4.00
Weighted Avg. Basic Shares Out.	7,817.00	7,442.00	6,813.00	6,346.00	6,176.00	6,089.00	5,970.00	5,872.00	5,569.00	5,555.00	5,601.00
Diluted EPS	1.27	1.94	3.19	1.42	1.11	1.17	3.52	1.87	2.82	1.71	3.85
Diluted EPS Excl. Extra Items	1.06	1.20	1.65	1.41	1.11	1.17	3.52	1.86	1.89	1.24	3.93
Weighted Avg. Diluted Shares Out.	7,870.00	7,508.00	6,895.00	6,424.00	6,257.00	6,159.00	6,058.00	5,977.00	5,675.00	5,632.00	5,708.00
Normalized Basic EPS	2.31	2.19	2.22	2.26	2.20	2.40	2.65	3.00	2.95	2.22	4.42
Normalized Diluted EPS	1.63	1.63	1.76	1.78	1.67	2.10	2.06	2.26	1.25	1.78	4.30
Dividends per Share											
Payout Ratio %	77.97	72.84	57.68	72.65	99.57	101.55	36.43	72.73	75.93	121.68	38.82
Supplemental Items											
EBITA	20,388.00	20,373.00	19,783.00	17,288.00	15,552.00	16,062.00	18,480.00	18,894.00	15,193.00	11,602.00	23,640.00
EBIT	14,803.00	15,264.00	15,184.00	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,817.00	8,166.00	19,433.00
As Reported Total Revenue*	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00
Effective Tax Rate %	31.77	19.76	27.40	25.49	22.20	13.45	-	5.94	5.15	6.36	7.62
Normalized Net Income	12,836.00	12,185.00	12,101.00	11,436.70	10,436.85	12,907.85	12,462.46	13,521.33	7,103.11	10,020.33	24,531.80
Interest Capitalized	50.00	41.00	32.00	41.00	32.00	61.00	72.00	73.00	88.00	96.00	108.00
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	419.00	481.00	523.00	586.00	669.00	691.00	840.00	949.00	687.00	756.00	1,182.00
Stock-Based Comp., Total	419.00	481.00	523.00	586.00	669.00	691.00	840.00	949.00	687.00	756.00	1,182.00

Ticker:	PFE US EQUITY
Period Type	Annuals

PFE US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	3,182.00	10,081.00	2,183.00	3,343.00	3,641.00	2,595.00	1,342.00	1,139.00	1,121.00	1,784.00	1,944.00
Short Term Investments	23,270.00	22,318.00	30,225.00	32,779.00	19,649.00	15,255.00	18,650.00	17,694.00	8,525.00	10,437.00	29,125.00
Total Cash & ST Investments	26,452.00	32,399.00	32,408.00	36,122.00	23,290.00	17,850.00	19,992.00	18,833.00	9,646.00	12,221.00	31,069.00
Accounts & Notes Receivable	13,058.00	10,675.00	9,357.00	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,930.00	11,479.00
Total Receivables	13,058.00	10,675.00	9,357.00	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,930.00	11,479.00
Inventories	6,610.00	6,076.00	6,166.00	5,663.00	7,513.00	6,783.00	7,579.00	7,509.00	7,068.00	8,046.00	9,059.00
Prepaid Exp.	-	-	-	-	-	-	-	-	-	-	-
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	14,697.00	15,681.00	8,313.00	5,409.00	4,825.00	6,091.00	5,349.00	15,559.00	9,317.00	6,870.00	8,086.00
Total Current Assets	60,817.00	64,831.00	56,244.00	55,595.00	43,804.00	38,949.00	41,141.00	49,926.00	32,803.00	35,067.00	59,693.00
Net Property, Plant & Equipment	15,921.00	13,213.00	12,397.00	11,760.00	13,766.00	13,318.00	13,865.00	13,385.00	14,257.00	15,293.00	17,721.00
Long-term Investments	9,814.00	14,149.00	16,406.00	17,518.00	15,999.00	7,116.00	7,015.00	2,767.00	20,147.00	20,262.00	21,526.00
Deferred Charges, LT	-	1,565.00	1,554.00	1,944.00	1,794.00	1,812.00	1,855.00	1,924.00	1,911.00	2,383.00	3,341.00
Other Long-Term Assets	101,450.00	92,040.00	85,500.00	80,749.00	92,018.00	110,420.00	107,921.00	91,420.00	98,476.00	81,224.00	79,195.00
Total Assets	188,002.00	185,798.00	172,101.00	167,566.00	167,381.00	171,615.00	171,797.00	159,422.00	167,594.00	154,229.00	181,476.00
LIABILITIES											
Accrued Exp.	2,120.00	1,875.00	1,792.00	1,841.00	2,359.00	2,487.00	2,196.00	2,397.00	2,390.00	3,058.00	3,332.00
Short-term Borrowings	4,016.00	6,424.00	6,027.00	5,141.00	10,159.00	10,688.00	9,953.00	8,831.00	16,464.00	3,024.00	2,690.00
Accounts Payable	3,678.00	2,921.00	3,234.00	3,210.00	3,620.00	4,536.00	4,656.00	4,674.00	3,887.00	4,309.00	5,578.00
Curr. Income Taxes Payable	1,009.00	979.00	678.00	531.00	418.00	437.00	477.00	1,265.00	980.00	1,049.00	1,266.00
Other Current Liabilities	18,086.00	16,987.00	11,635.00	10,864.00	12,842.00	12,967.00	13,145.00	14,691.00	13,582.00	14,480.00	29,806.00
Total Current Liabilities	28,909.00	29,186.00	23,366.00	21,587.00	29,398.00	31,115.00	30,427.00	31,858.00	37,303.00	25,920.00	42,672.00
Long-Term Debt	34,926.00	31,036.00	30,462.00	31,541.00	28,740.00	31,398.00	33,538.00	32,909.00	36,985.00	38,247.00	38,705.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	41,546.00	43,898.00	41,653.00	42,817.00	44,245.00	49,262.00	36,176.00	30,897.00	29,859.00	26,589.00	22,637.00
Total Liabilities	105,381.00	104,120.00	95,481.00	95,945.00	102,383.00	111,775.00	100,141.00	95,664.00	104,147.00	90,756.00	104,014.00
Pref. Stock, Non-Redeem.	45.00	39.00	33.00	29.00	26.00	24.00	21.00	19.00	17.00	-	-
Total Pref. Equity	45.00	39.00	33.00	29.00	26.00	24.00	21.00	19.00	17.00	-	-
Minority Interest	431.00	418.00	313.00	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00
Additional Paid In Capital	71,868.00	73,056.00	77,736.00	79,432.00	81,475.00	83,146.00	84,742.00	86,720.00	87,896.00	89,144.00	91,064.00
Retained Earnings	46,210.00	54,240.00	69,732.00	72,176.00	71,993.00	71,774.00	85,291.00	89,554.00	97,670.00	96,770.00	103,394.00
Treasury Stock	(31,801.00)	(40,122.00)	(67,923.00)	(73,021.00)	(79,252.00)	(84,364.00)	(89,425.00)	(101,610.00)	(110,801.00)	(110,988.00)	(111,361.00)
Comprehensive Inc. and Other	(4,132.00)	(5,953.00)	(3,271.00)	(7,316.00)	(9,522.00)	(11,036.00)	(9,321.00)	(11,276.00)	(11,638.00)	(11,688.00)	(5,897.00)
Total Common Equity	82,576.00	81,639.00	76,587.00	71,592.00	64,972.00	59,816.00	71,635.00	63,739.00	63,430.00	63,473.00	77,462.00
Total Equity	82,621.00	81,678.00	76,620.00	71,621.00	64,998.00	59,840.00	71,656.00	63,758.00	63,447.00	63,473.00	77,462.00
Total Liabilities And Equity	188,002.00	185,798.00	172,101.00	167,566.00	167,381.00	171,615.00	171,797.00	159,422.00	167,594.00	154,229.00	181,476.00
Supplemental Items											
Total Shares Out. on Filing Date	7,575.00	7,276.00	6,399.00	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00
Total Shares Out. on Balance Sheet Date	7,575.00	7,276.00	6,399.00	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00
Book Value/Share	10.84	11.16	11.92	11.33	10.48	9.81	11.92	11.09	11.41	11.36	13.74
Tangible Book Value	(13,608.00)	(7,586.00)	(5,630.00)	(5,965.00)	(23,904.00)	(47,577.00)	(33,405.00)	(25,234.00)	(19,011.00)	(14,810.00)	2,846.00
Tangible Book Value/Share	(1.80)	(1.04)	(0.88)	(0.95)	(3.87)	(7.84)	(5.59)	(4.41)	(3.44)	(2.66)	0.51
Total Debt	38,942.00	37,460.00	36,489.00	36,682.00	38,899.00	42,086.00	43,491.00	41,740.00	53,449.00	41,271.00	41,395.00
Net Debt	12,490.00	5,061.00	4,081.00	560.00	15,609.00	24,236.00	23,499.00	22,907.00	43,803.00	29,050.00	10,326.00
Total Minority Interest	431.00	418.00	313.00	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	785.00	448.00	505.00	510.00	867.00	793.00	788.00	546.00	672.00	738.00	994.00
Work in Progress Inventory	3,514.00	3,374.00	3,445.00	3,248.00	3,932.00	3,696.00	3,908.00	4,701.00	4,131.00	4,430.00	4,424.00
Finished Goods Inventory	2,311.00	2,254.00	2,216.00	1,905.00	2,714.00	2,294.00	2,883.00	2,262.00	2,265.00	2,878.00	3,641.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	226.00	324.00	478.00	412.00	384.00	609.00	584.00	541.00	493.00	508.00	492.00
Full Time Employees	103,700.00	91,500.00	77,700.00	78,300.00	97,900.00	96,500.00	90,200.00	92,400.00	88,000.00	78,500.00	79,000.00

Ticker: PFE US EQUITY
 Period Type: Annuals

Sort: Ascend
 Consolidated: Yes

Accounting: Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples		31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
TEV / LTM Total Revenue	Close	2.7x	3.4x	3.9x	4.0x	4.4x	4.2x	4.6x	5.1x	6.4x	5.6x	4.2x
	Average	2.5x	2.9x	3.8x	3.8x	4.2x	4.4x	4.3x	4.8x	4.6x	6.0x	6.3x
	High	2.8x	3.5x	4.2x	4.1x	4.5x	5.0x	4.7x	5.5x	6.4x	6.9x	8.9x
	Low	2.2x	2.6x	3.5x	3.5x	3.9x	3.9x	4.0x	4.3x	4.0x	4.9x	4.2x
TEV / LTM EBITDA	Close	7.5x	8.2x	9.3x	10.5x	12.7x	12.5x	12.0x	13.4x	12.5x	17.6x	13.6x
	Average	7.7x	7.9x	9.0x	9.2x	11.1x	12.7x	12.8x	12.7x	12.1x	11.8x	19.8x
	High	8.4x	8.7x	10.0x	10.5x	12.7x	14.3x	13.9x	14.6x	13.5x	17.5x	28.0x
	Low	6.7x	7.3x	8.3x	8.3x	10.2x	11.3x	12.0x	11.2x	10.4x	9.7x	13.6x
TEV / LTM EBIT	Close	11.9x	12.3x	13.2x	14.9x	18.2x	18.5x	17.5x	19.5x	17.6x	28.5x	17.6x
	Average	12.5x	12.6x	13.5x	13.0x	15.8x	18.3x	19.0x	18.5x	17.6x	16.7x	32.2x
	High	13.7x	14.0x	15.0x	14.9x	18.2x	20.5x	20.5x	21.2x	19.6x	28.5x	45.5x
	Low	10.9x	11.6x	12.5x	11.9x	14.4x	16.3x	17.5x	16.3x	15.2x	13.6x	17.5x
Price / LTM EPS	Close	13.3x	15.4x	17.4x	17.5x	19.4x	15.5x	17.6x	19.3x	31.2x	20.7x	13.7x
	Average	12.6x	13.5x	16.9x	16.3x	18.0x	18.6x	15.4x	18.0x	16.8x	27.8x	23.6x
	High	14.1x	15.1x	18.8x	17.6x	19.3x	21.2x	16.8x	21.3x	29.6x	33.9x	34.4x
	Low	10.8x	12.2x	15.1x	14.9x	16.4x	14.7x	14.1x	15.5x	14.4x	20.7x	13.7x
Price / Book Value	Close	2.0x	2.2x	2.6x	2.7x	3.1x	3.3x	3.0x	3.9x	3.4x	3.2x	4.3x
	Average	1.7x	2.0x	2.5x	2.4x	2.8x	3.0x	3.3x	3.1x	3.4x	3.1x	3.7x
	High	1.9x	2.3x	2.7x	2.6x	3.0x	3.4x	3.6x	3.7x	3.8x	3.7x	5.4x
	Low	1.4x	1.8x	2.2x	2.2x	2.6x	2.6x	2.9x	2.7x	2.9x	2.4x	2.9x
Price / Tangible Book Value	Close	--	--	--	--	--	--	--	--	--	--	116.6x
	Average	--	--	--	--	--	--	--	--	--	--	116.6x
	High	--	--	--	--	--	--	--	--	--	--	116.6x
	Low	--	--	--	--	--	--	--	--	--	--	116.6x
Price / Cash Flow	Close	8.4x	11.1x	11.8x	11.6x	13.6x	12.4x	12.9x	16.2x	17.3x	14.2x	10.2x
	Average	13.0x	8.5x	12.2x	11.1x	11.9x	13.1x	12.4x	13.2x	14.1x	15.4x	16.2x
	High	14.5x	10.6x	13.6x	12.0x	12.9x	14.9x	13.5x	15.6x	16.4x	18.8x	23.6x
	Low	7.9x	7.7x	10.9x	10.1x	10.9x	11.4x	11.3x	11.3x	12.0x	11.9x	10.2x
TEV / LTM FCF	Close	9.1x	12.1x	12.7x	12.4x	15.0x	14.0x	14.6x	18.6x	20.7x	16.8x	11.1x
	Average	14.9x	9.3x	13.3x	11.9x	12.8x	14.5x	14.0x	14.9x	16.1x	18.4x	19.2x
	High	16.7x	11.5x	14.7x	12.8x	14.2x	16.4x	15.3x	17.6x	19.6x	22.5x	28.0x
	Low	8.6x	8.4x	11.8x	10.9x	11.7x	12.6x	12.8x	12.8x	13.8x	14.3x	11.1x
Dividend Yield	Close	3.7	3.5	3.1	3.3	3.5	3.7	3.6	3.2	3.7	4.2	2.6
	Average	3.9	3.7	3.2	3.3	3.3	3.6	3.7	3.5	3.7	4.2	3.7
	High	4.6	4.0	3.6	3.7	3.7	4.1	4.1	4.1	4.3	5.4	4.6
	Low	3.5	3.2	2.9	3.1	3.0	3.2	3.4	3.0	3.3	3.4	2.5

Ticker:	PFE US EQUITY
Period Type:	Quarters

PFE US EQUITY	Ascend
Consolidated	Yes

Accounting	Mixed
------------	-------

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FQ	-9FQ	-8FQ	-7FQ	-6FQ	-5FQ	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
Ratios											
For the Fiscal Period Ending	29/03/2020	28/06/2020	27/09/2020	31/12/2020	04/04/2021	04/07/2021	03/10/2021	31/12/2021	03/04/2022	03/07/2022	02/10/2022
Profitability											
Return on Assets	9.8%	8.5%	4.6%	5.7%	6.6%	7.3%	10.9%	13.1%	14.6%	16.1%	15.9%
Return on Capital	15.5%	13.1%	7.4%	9.5%	10.6%	11.8%	17.0%	20.8%	23.0%	25.7%	25.2%
Return on Equity	25.4%	22.9%	12.2%	14.5%	16.0%	19.0%	27.6%	31.3%	33.1%	37.3%	35.4%
Margin Analysis											
Gross Margin	80.8%	81.5%	80.5%	75.3%	71.4%	63.0%	58.7%	59.2%	61.1%	68.8%	73.2%
SG&A Margin	24.3%	25.6%	24.9%	30.8%	18.2%	14.7%	11.3%	16.5%	9.7%	10.5%	14.3%
EBITDA Margin	52.9%	51.0%	32.2%	31.0%	31.7%	33.1%	31.8%	30.2%	31.7%	35.3%	38.4%
EBIT Margin	40.6%	38.7%	19.9%	19.6%	21.3%	24.2%	24.7%	23.9%	26.1%	30.4%	33.6%
Earnings from Cont. Ops Margin	30.1%	21.0%	23.8%	5.6%	32.3%	29.7%	25.6%	12.5%	36.6%	44.0%	39.5%
Net Income Margin	33.3%	35.4%	14.3%	7.3%	33.6%	29.4%	33.9%	14.2%	30.6%	35.7%	38.0%
Normalized Net Income Margin	27.7%	28.4%	22.1%	15.8%	32.4%	29.5%	25.8%	24.6%	34.9%	38.4%	42.1%
Free Cash Flow Margin	26.6%	31.4%	14.9%	41.6%	27.4%	56.9%	42.5%	20.6%	23.0%	26.7%	40.2%
Asset Turnover											
Total Asset Turnover	0.3x	0.3x	0.2x	0.3x	0.3x	0.3x	0.4x	0.5x	0.5x	0.6x	0.5x
Fixed Asset Turnover	3.2x	3.0x	2.8x	2.8x	3.3x	3.9x	4.8x	4.9x	6.3x	6.9x	6.7x
Accounts Receivable Turnover	4.8x	4.6x	4.2x	5.7x	4.7x	5.6x	6.3x	8.4x	8.0x	7.9x	7.1x
Inventory Turnover	1.1x	1.0x	0.9x	1.1x	1.3x	1.8x	2.7x	3.6x	4.0x	3.9x	3.8x
Short Term Liquidity											
Current Ratio	1.0x	1.4x	1.4x	1.4x	1.5x	1.4x	1.4x	1.4x	1.4x	1.4x	1.6x
Quick Ratio	0.6x	0.6x	0.6x	0.8x	0.9x	0.9x	1.0x	1.0x	0.9x	1.0x	1.2x
Cash from Ops. To Curr Liab	0.3x	0.3x	0.3x	0.5x	0.5x	0.6x	0.7x	0.7x	0.6x	0.7x	0.8x
Ave. Davs Sales Out.	76.3x	79.9x	87.0x	64.3x	79.1x	66.1x	58.8x	43.6x	45.5x	46.3x	51.0x
Ave. Davs Inventory Out.	325.3x	361.6x	405.6x	320.1x	289.0x	202.7x	138.9x	101.3x	91.7x	92.2x	96.0x
Ave. Davs Pavaible Out.	154.1x	163.1x	164.7x	155.9x	136.4x	97.7x	70.4x	56.7x	45.7x	48.7x	56.5x
Ave. Cash Conversion Cycle	247.5x	278.4x	328.0x	228.4x	231.7x	176.1x	127.3x	88.2x	91.5x	90.3x	90.4x
Long Term Solvency											
Total Debt/Equity	80.0%	98.5%	96.4%	65.0%	57.6%	55.8%	52.5%	53.4%	43.9%	46.1%	39.5%
Total Debt/Capital	44.5%	49.6%	49.1%	39.4%	36.6%	35.8%	34.4%	34.8%	30.5%	31.5%	28.3%
LT Debt/Equity	55.8%	78.6%	76.3%	60.5%	51.5%	50.5%	47.9%	50.1%	43.3%	39.3%	35.2%
LT Debt/Capital	30.8%	39.4%	38.7%	36.5%	32.6%	32.3%	31.3%	32.6%	30.0%	26.8%	25.2%
Total Liabilities/Total Assets	40.3%	45.3%	44.3%	42.0%	39.9%	37.6%	34.3%	33.8%	33.7%	30.9%	29.8%
EBIT / Interest Exp.	7.78x	5.65x	7.10x	1.89x	13.96x	17.74x	18.91x	9.50x	29.20x	41.70x	28.76x
EBITDA / Interest Exp.	10.77x	8.91x	11.06x	4.90x	17.55x	21.88x	23.04x	13.55x	32.88x	45.71x	32.56x
(EBITDA-CAPEX) / Interest Exp.	9.62x	7.67x	9.43x	2.64x	15.90x	20.18x	21.14x	10.40x	30.89x	43.15x	29.86x
Total Debt/EBITDA	2.13x	2.90x	4.83x	3.18x	2.70x	2.14x	1.81x	1.69x	1.24x	1.13x	0.96x
Net Debt/EBITDA	1.71x	2.38x	4.02x	2.24x	1.77x	0.96x	0.46x	0.42x	0.42x	0.20x	0.01x
Altman Z Score	4.44	3.91	3.6	4.18	4.16	4.04	4.18	4.81	5.06	4.99	4.95
Growth Over Prior Year											
Total Revenue	(23.1%)	(25.6%)	(19.0%)	11.3%	44.0%	91.6%	133.9%	104.9%	76.8%	46.8%	(5.8%)
Gross Profit	(23.8%)	(24.8%)	(17.9%)	4.8%	27.2%	48.1%	70.5%	60.9%	51.3%	60.4%	17.5%
EBITDA	(30.6%)	(44.4%)	(70.0%)	(5.3%)	40.4%	111.4%	96.3%	150.8%	79.6%	93.7%	35.2%
EBIT	(30.6%)	(46.0%)	(71.8%)	(5.8%)	42.9%	121.8%	105.9%	174.7%	84.5%	99.9%	37.7%
Earnings from Cont. Ops	(31.3%)	(51.4%)	(77.8%)	23.8%	54.6%	170.6%	151.1%	355.9%	100.5%	118.0%	45.5%
Net Income	(36.2%)	(48.5%)	(88.1%)	(160.8%)	96.7%	123.7%	791.1%	464.4%	61.3%	69.5%	5.8%
Normalized Net Income	(32.9%)	(30.9%)	(80.9%)	(351.8%)	45.4%	59.4%	454.5%	300.6%	61.2%	78.1%	5.7%
Diluted EPS before Extra	(32.9%)	(24.8%)	(31.4%)	28.7%	67.9%	98.4%	172.8%	219.4%	90.4%	91.6%	53.5%
	(35.3%)	(48.3%)	(88.2%)	(157.9%)	95.5%	121.7%	793.8%	463.6%	59.3%	69.6%	5.6%
Accounts Receivable	2.9%	(6.8%)	6.1%	17.1%	(0.2%)	16.0%	18.8%	44.8%	34.1%	43.1%	35.1%
Inventory	4.9%	4.0%	13.1%	13.8%	0.8%	4.5%	(7.0%)	12.6%	17.5%	16.8%	10.1%
Net PP&E	(4.8%)	(4.6%)	(4.0%)	7.3%	(0.2%)	0.8%	0.2%	15.9%	7.8%	7.2%	7.0%
Total Assets	7.0%	13.9%	5.0%	(8.0%)	(4.5%)	(4.5%)	0.1%	17.7%	15.8%	14.9%	9.0%
Tangible Book Value	(2.6%)	3.3%	(21.9%)	(22.6%)	(67.5%)	(74.1%)	(99.6%)	(119.0%)	(126.2%)	(214.4%)	(14,559.9%)
Common Equity	10.6%	8.0%	0.3%	0.2%	5.6%	8.9%	16.0%	22.1%	20.1%	24.5%	22.4%
Cash from Ops	84.5%	36.7%	(53.7%)	49.7%	44.8%	217.8%	418.1%	5.1%	44.1%	(27.7%)	(8.3%)
Capital Expenditures	(2.4%)	(4.6%)	(0.7%)	38.2%	23.4%	17.5%	10.2%	26.5%	16.1%	39.9%	36.1%
Levered Free Cash Flow	116.8%	45.3%	(61.2%)	51.2%	48.4%	247.4%	567.8%	1.7%	48.0%	(31.1%)	(10.9%)
Unlevered Free Cash Flow	(171.7%)	659.2%	(130.0%)	125.6%	213.0%	769.2%	(1,476.7%)	0.1%	101.4%	(39.7%)	(14.7%)
Dividend per Share	5.6%	5.6%	5.6%	5.6%	2.6%	5.3%	2.6%	2.6%	2.6%	0.0%	2.6%

CAGR Over Two Years											
Total Revenue	(11.6%)	(14.4%)	(12.1%)	(8.8%)	5.2%	19.4%	37.7%	51.0%	59.5%	67.7%	48.4%
Gross Profit	(11.3%)	(12.7%)	(11.7%)	(10.3%)	(1.5%)	5.5%	18.3%	29.9%	38.8%	54.1%	41.6%
EBITDA	(12.8%)	(23.1%)	(15.8%)	(34.4%)	(1.3%)	8.4%	(23.2%)	54.1%	58.8%	102.4%	62.9%
EBIT	(13.1%)	(24.6%)	(17.0%)	(36.5%)	(0.4%)	9.4%	(23.8%)	60.9%	62.4%	110.6%	68.1%
FRIT	(12.4%)	(27.8%)	(19.4%)	(46.7%)	3.1%	14.6%	(25.4%)	137.6%	76.1%	147.8%	91.1%
Earnings from Cont. Ops.	(16.6%)	(18.1%)	(52.8%)	--	12.1%	7.3%	3.1%	--	78.1%	94.8%	207.0%
Net Income	(2.9%)	(5.1%)	(40.2%)	--	12.1%	5.0%	3.0%	--	53.1%	68.5%	142.1%
Normalized Net Income	(11.9%)	(11.5%)	(22.3%)	--	6.2%	22.2%	36.8%	102.7%	78.8%	95.0%	104.7%
Diluted EPS before Extra	(13.6%)	(15.9%)	(51.8%)	--	12.5%	7.1%	2.5%	--	76.5%	93.9%	207.2%
Accounts Receivable	2.2%	(3.8%)	(0.1%)	(0.6%)	1.4%	4.0%	12.3%	30.2%	15.7%	28.9%	26.7%
Inventory	1.7%	3.0%	6.6%	3.5%	2.8%	4.3%	2.5%	13.2%	8.8%	10.5%	1.2%
Net PP&F	0.2%	0.7%	1.3%	6.9%	(2.5%)	(1.9%)	(1.9%)	11.5%	3.7%	3.9%	3.5%
Total Assets	0.5%	3.9%	3.3%	(1.6%)	1.1%	4.3%	2.5%	4.1%	5.1%	4.8%	4.5%
Tangible Book Value	(6.8%)	(5.4%)	(5.7%)	(27.4%)	(43.8%)	(48.3%)	(94.4%)	--	--	--	--
Common Equity	(3.7%)	(4.0%)	(4.3%)	(0.1%)	8.0%	8.5%	7.8%	10.6%	12.6%	16.4%	19.1%
Cash from Ops.	25.7%	(3.9%)	(37.0%)	9.0%	63.5%	108.0%	55.0%	25.3%	44.5%	51.6%	118.0%
Capital Expenditures	7.9%	3.8%	1.3%	7.1%	9.7%	5.9%	4.6%	32.2%	19.7%	28.2%	22.4%
Levered Free Cash Flow	29.6%	(4.9%)	(43.0%)	9.3%	79.4%	124.7%	60.9%	24.0%	48.2%	54.8%	143.9%
Unlevered Free Cash Flow	--	(17.0%)	--	14.2%	--	712.4%	103.3%	50.3%	151.0%	129.0%	--
Dividend per Share	5.7%	5.7%	5.7%	5.7%	4.1%	5.4%	4.1%	4.1%	2.6%	2.6%	2.6%
CAGR Over Three Years											
Total Revenue	(7.6%)	(8.5%)	(7.9%)	(5.3%)	4.0%	12.0%	21.8%	19.5%	25.1%	27.9%	21.3%
Gross Profit	(7.6%)	(7.7%)	(7.1%)	(5.7%)	0.1%	4.1%	10.0%	9.0%	13.6%	21.3%	18.0%
EBITDA	(9.0%)	(14.9%)	(10.0%)	(24.0%)	2.7%	7.7%	11.7%	7.6%	20.5%	31.6%	(7.3%)
EBIT	(9.3%)	(15.9%)	(10.6%)	(25.6%)	2.5%	8.1%	12.4%	3.5%	22.3%	33.8%	(7.3%)
EBIT	(8.9%)	(17.9%)	(12.6%)	(34.2%)	5.9%	12.1%	17.8%	9.0%	28.7%	42.0%	(6.8%)
Earnings from Cont. Ops.	(7.4%)	(5.4%)	(31.5%)	(62.8%)	11.0%	14.5%	25.7%	(310.6%)	26.5%	25.0%	4.0%
Net Income	2.4%	4.3%	(19.7%)	(59.0%)	11.1%	12.8%	25.6%	(305.0%)	26.5%	25.2%	3.9%
Normalized Net Income	(4.4%)	(7.0%)	(11.5%)	(15.1%)	9.2%	15.9%	18.1%	(260.1%)	29.0%	41.9%	42.2%
Diluted EPS before Extra	(4.8%)	(3.4%)	(30.2%)	(62.1%)	13.4%	16.2%	27.5%	(306.9%)	26.3%	24.8%	3.5%
Accounts Receivable	3.6%	(1.2%)	0.0%	(1.7%)	1.4%	2.4%	5.9%	12.7%	11.3%	15.7%	19.4%
Inventory	4.3%	4.1%	5.5%	2.0%	1.4%	3.5%	1.8%	6.5%	7.5%	8.3%	5.0%
Net PP&E	2.0%	1.8%	2.2%	3.3%	0.1%	0.7%	0.9%	9.8%	0.8%	1.0%	1.0%
Total Assets	(0.5%)	1.8%	1.3%	(3.5%)	(1.7%)	1.0%	2.7%	4.4%	5.8%	7.7%	4.7%
Tangible Book Value	(14.8%)	(14.9%)	(15.2%)	(21.9%)	(34.4%)	(38.6%)	(84.6%)	(148.6%)	(143.6%)	(167.4%)	(176.9%)
Common Equity	3.6%	3.3%	2.4%	(3.9%)	(0.7%)	0.1%	2.0%	6.8%	11.9%	13.6%	12.5%
Cash from Ops.	25.5%	3.2%	(24.7%)	(7.4%)	31.8%	43.2%	27.2%	7.7%	56.8%	46.3%	30.1%
Capital Expenditures	7.8%	0.7%	7.6%	3.9%	12.8%	8.2%	4.2%	13.2%	11.8%	16.2%	14.2%
Levered Free Cash Flow	29.8%	3.5%	(29.9%)	(8.8%)	35.6%	46.5%	29.4%	6.7%	68.3%	51.5%	32.1%
Unlevered Free Cash Flow	(193.1%)	3.9%	(161.2%)	(15.2%)	(260.9%)	81.5%	43.5%	9.3%	(265.4%)	241.4%	52.2%
Dividend per Share	5.9%	5.9%	5.9%	5.9%	4.7%	5.6%	4.7%	4.7%	3.6%	3.6%	3.6%
CAGR Over Five Years											
Total Revenue	(1.5%)	(3.6%)	(3.2%)	(3.7%)	2.7%	7.5%	13.0%	11.8%	15.0%	16.6%	11.4%
Gross Profit	(2.0%)	(3.6%)	(3.5%)	(3.8%)	0.4%	3.6%	7.2%	6.3%	8.7%	13.3%	9.9%
EBITDA	(0.5%)	(7.4%)	(3.8%)	(12.2%)	2.1%	7.3%	11.1%	6.1%	13.7%	20.3%	14.1%
EBIT	(0.5%)	(8.0%)	(4.3%)	(12.6%)	2.5%	8.0%	12.3%	7.6%	14.5%	21.4%	15.1%
EBIT	(0.0%)	(10.4%)	(6.1%)	(18.6%)	3.8%	10.0%	15.3%	13.1%	18.6%	26.7%	19.5%
Earnings from Cont. Ops.	0.9%	(0.2%)	(15.5%)	(230.7%)	9.9%	23.1%	43.2%	36.2%	20.3%	26.3%	24.8%
Net Income	7.1%	5.8%	(7.2%)	(237.6%)	9.9%	22.1%	43.2%	34.4%	20.3%	26.4%	24.8%
Normalized Net Income	2.8%	(0.9%)	(6.5%)	(2.2%)	5.2%	7.9%	17.3%	17.9%	22.8%	25.1%	23.8%
Diluted EPS before Extra	3.0%	1.8%	(14.0%)	(229.7%)	11.9%	25.3%	45.4%	38.9%	21.9%	27.7%	26.3%
Accounts Receivable	2.1%	0.4%	1.0%	(0.6%)	1.8%	3.0%	3.9%	6.9%	8.3%	9.8%	10.0%
Inventory	7.8%	8.1%	3.9%	1.4%	2.3%	3.3%	2.9%	6.0%	6.1%	6.6%	3.7%
Net PP&E	4.0%	4.3%	1.0%	2.1%	0.6%	0.9%	1.7%	5.9%	2.7%	2.6%	2.7%
Total Assets	0.7%	2.0%	0.9%	(1.6%)	(0.5%)	(0.1%)	0.1%	1.1%	1.7%	3.0%	2.6%
Tangible Book Value	28.3%	30.5%	3.7%	(7.2%)	(17.0%)	(24.0%)	(70.1%)	(157.8%)	(155.5%)	(171.2%)	(181.3%)
Common Equity	(0.7%)	(0.8%)	(0.5%)	(0.5%)	1.7%	2.2%	3.6%	5.3%	7.1%	8.4%	8.8%
Cash from Ops.	35.7%	(2.8%)	(16.1%)	2.8%	20.2%	25.7%	18.0%	0.6%	32.8%	20.3%	15.2%
Capital Expenditures	13.4%	12.1%	14.2%	5.1%	13.0%	6.0%	7.4%	7.6%	12.4%	10.9%	13.3%
Levered Free Cash Flow	43.5%	(4.2%)	(20.2%)	2.5%	21.4%	27.4%	18.9%	(0.6%)	36.9%	21.6%	15.4%
Unlevered Free Cash Flow	(184.8%)	(14.1%)	(172.0%)	1.3%	(239.3%)	44.1%	26.4%	(3.4%)	(238.4%)	42.5%	21.9%
Dividend per Share	6.3%	6.3%	6.3%	6.3%	5.4%	5.9%	5.4%	5.4%	4.6%	4.6%	4.6%

Ticker: PFE US EQUITY	Sort: Ascend	Currency: Reporting	Change	USD
Period Type: Quarters	Consolidated: Yes	Accounting: Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
WACC					
For the Fiscal Period Ending	03/10/2021	31/12/2021	03/04/2022	03/07/2022	02/10/2022
	%	%	%	%	%
Equity					
Cost of Equity	8.0%	7.2%	6.7%	8.0%	7.9%
Weight of Equity	85.8%	88.9%	88.8%	87.9%	87.0%
+ Debt					
Cost of Debt	1.6%	1.7%	2.7%	3.3%	4.3%
Weight of Debt	14.2%	11.1%	11.2%	12.1%	13.0%
+ Preferred Equity					
Cost of Pref Equity	--	--	--	--	--
Weight of Pref Equity	0.0%	0.0%	0.0%	0.0%	0.0%
WACC	7.1%	6.6%	6.2%	7.4%	7.5%

Capital Structure											
For the Fiscal Period Ending	03/10/2021		31/12/2021		03/04/2022		03/07/2022		02/10/2022		
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	
Hist Market Cap											
ST Borrowings	3,629.0	1.3%	2,690.0	0.7%	645.0	0.2%	5,990.0	1.8%	4,040.0	1.4%	
LT Borrowings	36,250.0	12.9%	38,705.0	10.4%	35,656.0	11.0%	34,294.0	10.3%	32,629.0	11.6%	
Pref Equity	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%	
Total Capital	280,759.2	100.0%	373,256.0	100.0%	324,628.9	100.0%	332,853.8	100.0%	282,250.1	100.0%	

Debt Summary Data											
For the Fiscal Period Ending	03/10/2021		31/12/2021		03/04/2022		03/07/2022		02/10/2022		
Currency	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	
Total Commercial Paper	100.0	0.3%	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%	
Total Revolving Credit	7,000.0	17.6%	7,038.0	17.0%	7,000.0	19.3%	7,000.0	17.4%	7,000.0	19.1%	
Total Capital Leases	--	--	--	--	--	--	--	--	--	--	
General/Other Borrowings				83.0%	29,301.0	80.7%		82.6%	29,669.0	80.9%	
Total Principal Due	39,879.0	100.0%	41,395.0	100.0%	36,301.0	100.0%	40,284.0	100.0%	36,669.0	100.0%	
Total Debt Outstanding	39,879.0		41,395.0		36,301.0		40,284.0		36,669.0		
Additional Totals											
Total Cash & ST Investments	29,696.0	74.5%	31,069.0	75.1%	23,897.0	65.8%	33,304.0	82.7%	36,123.0	98.5%	
Net Debt	10,183.0	25.5%	10,326.0	24.9%	12,404.0	34.2%	6,980.0	17.3%	546.0	1.5%	
Total Short-Term Borrowings	3,629.0	9.1%	2,690.0	6.5%	645.0	1.8%	5,990.0	14.9%	4,040.0	11.0%	
Curr. Port. of LT Debt/Cap. Leases	3,629.0	9.1%	2,690.0	6.5%	645.0	1.8%	5,990.0	14.9%	4,040.0	11.0%	
Long-Term Debt (Incl. Cap. Leases)	36,250.0	90.9%	38,705.0	93.5%	35,656.0	98.2%	34,294.0	85.1%	32,629.0	89.0%	
Total Secured Debt	--	--	--	--	--	--	--	--	--	--	
Fixed Rate Debt	--	--	--	--	--	--	--	--	--	--	
Variable Rate Debt	--	--	--	--	--	--	--	--	--	--	
Credit Ratios											
Net Debt/EBITDA	0.5x		0.4x		0.4x		0.2x		0.0x		
Total Debt/EBITDA	1.8x		1.7x		1.2x		1.1x		1.0x		
Operating Income/Total Debt	0.2x		0.1x		0.3x		0.3x		0.2x		
LTM FCF/Total Debt	0.7x		0.7x		0.9x		0.7x		0.7x		
LTM CFO/Total Debt	0.8x		0.8x		1.0x		0.8x		0.8x		
EBIT/Interest Expense	18.9x		9.5x		29.2x		41.7x		28.8x		
EBIT/Total Interest Expense	18.9x		9.5x		29.2x		41.7x		28.8x		
Degree of Financial Leverage	1.1x		1.1x		1.0x		1.0x		1.0x		
(EBITDA-CAPEX)/Interest Expense	21.1x		10.4x		30.9x		43.2x		29.9x		
EBITDA/Total Interest Expense	23.0x		13.5x		32.9x		45.7x		32.6x		

Debt Schedule											
Debt Schedule In Yr 1	--	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 2	--	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 3	--	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 4	--	--	--	--	--	--	--	--	--	--	--
Debt Schedule In Yr 5	--	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 2 - 3	--	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 4 - 5	--	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Years 2 - 5	--	--	--	--	--	--	--	--	--	--	--
Debt Schedule Beyond Yr 5	--	--	--	--	--	--	--	--	--	--	--
Debt Schedule - Total Debt	39,878.0	100.0%	38,436.0	100.0%	36,301.0	100.0%	40,284.0	100.0%	36,669.0	100.0%	

Capital Lease Schedule											
Capital Leases - Year 1	--	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 2	--	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 3	--	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 4	--	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 5	--	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 3	--	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 4 - 5	--	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 5	--	--	--	--	--	--	--	--	--	--	--
Capital Leases Beyond Year 5	--	--	--	--	--	--	--	--	--	--	--
Total Future Value of Capital Leases	--	--	--	--	--	--	--	--	--	--	--
Present Value of ST Capital Leases	--	--	--	--	--	--	--	--	--	--	--
Present Value of LT Capital Leases	--	--	--	--	--	--	--	--	--	--	--

Operating Leases (Rental Expense) Schedule											
Rental Expense - Year 1	--	--	520.0	14.4%	--	--	--	--	--	--	--
Rental Expense - Year 2	--	--	417.0	11.5%	--	--	--	--	--	--	--
Rental Expense - Year 3	--	--	322.0	8.9%	--	--	--	--	--	--	--
Rental Expense - Year 4	--	--	279.0	7.7%	--	--	--	--	--	--	--
Rental Expense - Year 5	--	--	218.0	6.0%	--	--	--	--	--	--	--
Rental Expense - Years 2 - 3	--	--	739.0	20.4%	--	--	--	--	--	--	--
Rental Expense - Years 4 - 5	--	--	497.0	13.7%	--	--	--	--	--	--	--
Rental Expense - Years 2 - 5	--	--	1,236.0	34.1%	--	--	--	--	--	--	--
Rental Expense Beyond Year 5	--	--	1,865.0	51.5%	--	--	--	--	--	--	--
Total Sublease Income	--	--	--	--	--	--	--	--	--	--	--
Future Min Oper Lease Obligations	--	--	3,621.0	100.0%	--	--	--	--	--	--	--

Contractual Obligation Schedule											
Contractual Obligations - Year 1	--	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 2-3	--	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 4-5	--	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 2 - 5	--	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Beyond Year 5	--	--	--	--	--	--	--	--	--	--	--
Total Contractual Obligations	--	--	--	--	--	--	--	--	--	--	--

Purchase Obligations	--		5,200.0		--		--		--		--
-----------------------------	----	--	----------------	--	----	--	----	--	----	--	----

Interest Rate Data											
W/Avg. Interest Rate - Long-term Debt	--		--		--		--		--		--

Ticker: PFE US EQUITY	Sort Ascend	Currency Reporting Change USD
Period Type: Annuals	Consolidated Yes	Accounting Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	630.00	607.00	543.00	472.00	495.00	440.00	464.00	136.00	125.00	146.00	130.00
Interest Cost	1,249.00	1,165.00	1,111.00	1,148.00	1,037.00	932.00	892.00	865.00	891.00	697.00	601.00
Expected Return on Plan Assets	(1,308.00)	(1,407.00)	(1,406.00)	(1,502.00)	(1,507.00)	(1,339.00)	(1,350.00)	(1,400.00)	(1,207.00)	(1,321.00)	(1,379.00)
Pension Expense (Income)	994.00	926.00	928.00	402.00	1,203.00	696.00	695.00	(2.00)	331.00	70.00	(2,011.00)
Other Postretirement Cost											
Service Cost	68.00	68.00	61.00	55.00	55.00	41.00	42.00	39.00	37.00	38.00	36.00
Interest Cost	195.00	182.00	166.00	169.00	117.00	101.00	90.00	72.00	75.00	49.00	29.00
Expected Return on Plan Assets	(35.00)	(46.00)	(55.00)	(63.00)	(53.00)	(34.00)	(36.00)	(37.00)	(33.00)	(36.00)	(42.40)
Other Postretirement Benefits Expense (I)	127.00	129.00	163.00	102.00	(21.00)	(59.00)	(75.00)	(111.00)	(146.00)	(118.00)	(372.00)
Pension Funded Status											
Fair Value of Plan Assets	18,958.00	20,129.00	21,119.00	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00
Actual Return (Loss) on Plan Assets	574.00	2,132.00	2,294.00	1,865.00	166.00	1,632.00	2,816.00	(873.00)	3,633.00	2,842.00	-
Employer Contribution	2,640.00	585.00	557.00	493.00	1,716.00	1,360.00	1,398.00	838.00	385.00	1,629.00	451.00
Benefits Paid	(989.00)	(912.00)	(1,017.00)	(1,163.00)	(866.00)	(998.00)	(932.00)	(977.00)	(978.00)	(817.00)	(886.00)
Projected Benefit Obligation	25,157.00	28,044.00	25,633.00	28,852.00	25,482.00	26,687.00	28,804.00	26,373.00	28,945.00	30,307.00	28,807.00
Over(Under) Funded Pension	(6,199.00)	(7,915.00)	(4,514.00)	(7,558.00)	(5,890.00)	(6,448.00)	(5,657.00)	(5,107.00)	(5,403.00)	(4,402.00)	(1,732.00)
Accumulated Benefit Obligation	19,470.00	22,391.00	18,346.00	-	-	-	-	-	-	-	-
Pension Funding Ratio	75.36	71.78	82.39	73.80	76.89	75.84	80.36	80.64	81.33	85.48	93.99
Other Postretirement Funded Status											
Fair Value of Plan Assets	422.00	644.00	741.00	762.00	622.00	458.00	494.00	469.00	519.00	588.00	753.00
Actual Return (Loss) on Plan Assets	9.00	85.00	98.00	45.00	(3.00)	44.00	39.00	(22.00)	50.00	69.00	-
Employer Contribution	250.00	353.00	244.00	210.00	84.00	16.00	183.00	145.00	137.00	113.00	145.00
Benefits Paid	(296.00)	(274.00)	(314.00)	(309.00)	(300.00)	(282.00)	(280.00)	(249.00)	(221.00)	(201.00)	-
Projected Benefit Obligation	3,900.00	4,165.00	3,438.00	3,168.00	2,463.00	2,254.00	2,028.00	1,870.00	1,667.00	1,238.00	995.00
Over(Under) Funded Post Ret Benefits	(3,478.00)	(3,521.00)	(2,697.00)	(2,406.00)	(1,841.00)	(1,796.00)	(1,534.00)	(1,401.00)	(1,148.00)	(650.00)	(242.00)
Other Post-Retirement Funding Ratio	10.82	15.46	21.55	24.05	25.25	20.32	24.36	25.08	31.13	47.50	75.68
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	7.58	7.52	7.37	7.41	8.30	7.07	8.00	7.50	7.20	7.00	6.80
Discount Rate used on Plan Liabilities	4.95	4.10	4.66	3.74	4.50	3.78	3.80	4.40	3.30	2.60	2.60
Rate of Compensation Increase	3.43	2.85	2.92	2.76	2.80	2.74	2.80	2.80	-	-	-
Other Postretirement Benefits											
Expected Return on Plan Assets	8.50	8.50	8.50	8.50	8.30	8.00	8.00	7.50	7.30	7.00	6.80
Discount Rate used on Plan Liabilities	4.80	4.10	5.10	4.20	4.50	4.20	3.70	4.30	3.20	2.50	2.90
Health Care Cost Trend Projected(next y)	7.80	7.50	7.30	7.00	-	-	-	-	-	-	-
Pension Plan Asset Allocation											
Fair Value of Plan Assets	18,958.00	20,129.00	21,119.00	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00
Asset Category - Equities %	41.12	48.03	51.65	41.23	40.20	40.10	37.50	31.30	31.80	28.40	20.00
Asset Category - Debt %	31.26	33.79	30.05	34.52	35.00	34.90	39.60	47.10	48.70	50.20	60.00
Asset Category - Real Estate %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Company Stock %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Cash %	12.71	3.31	2.79	5.84	3.60	5.30	4.60	3.40	2.50	4.90	5.00
Asset Category - Other %	9.77	10.02	11.36	18.41	21.20	19.70	18.30	18.20	17.00	16.60	15.00
Expected Pension Payments											
Year 1	1,398.00	1,721.00	1,368.00	1,408.00	1,476.00	2,002.00	1,753.00	1,908.00	2,021.00	1,637.00	1,680.00
Year 2	1,382.00	1,319.00	1,313.00	1,364.00	2,124.00	1,519.00	1,573.00	1,582.00	1,560.00	1,532.00	1,527.00
Year 3	1,415.00	1,329.00	1,320.00	1,439.00	1,462.00	1,400.00	1,600.00	1,552.00	1,527.00	1,523.00	1,523.00
Year 4	1,420.00	1,353.00	1,396.00	1,540.00	1,416.00	1,421.00	1,575.00	1,518.00	1,522.00	1,521.00	1,481.00
Year 5	1,435.00	1,412.00	1,511.00	1,462.00	1,443.00	1,398.00	1,556.00	1,508.00	1,506.00	1,479.00	1,455.00
Beyond Year 5	8,093.00	7,552.00	7,383.00	7,546.00	6,988.00	6,761.00	7,479.00	7,350.00	7,186.00	7,135.00	7,032.00
Expected Postretirement Benefits											
Year 1	295.00	295.00	286.00	261.00	198.00	186.00	173.00	166.00	153.00	97.00	78.00
Year 2	308.00	306.00	285.00	211.00	205.00	196.00	179.00	171.00	137.00	94.00	73.00
Year 3	317.00	313.00	293.00	216.00	208.00	198.00	181.00	171.00	137.00	92.00	69.00
Year 4	326.00	321.00	303.00	220.00	208.00	197.00	179.00	168.00	136.00	89.00	66.00
Year 5	331.00	329.00	311.00	222.00	207.00	196.00	173.00	165.00	134.00	86.00	68.00
Beyond Year 5	1,780.00	1,748.00	1,661.00	1,146.00	1,001.00	919.00	802.00	777.00	642.00	430.00	359.00

